Marea Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody medicines for cardioendocrine diseases, using human genetics to identify targets. Lead programs include an anti-ANGPTL4 antibody in Phase 2b for severe hypertriglyceridemia and a growth hormone receptor antagonist antibody for acromegaly.